Pser2 ctd of rpb1

Manufactured by Cell Signaling Technology

The PSer2-CTD of Rpb1 is a laboratory instrument used to detect and quantify the phosphorylation of serine 2 residues within the C-terminal domain (CTD) of the largest subunit of RNA polymerase II (Rpb1). This tool allows researchers to study the regulation of transcription elongation in eukaryotic cells.

Automatically generated - may contain errors

Lab products found in correlation

Ps62 myc, by Abcam (1 mentions) α tubulin, by Cell Signaling Technology (1 mentions) β actin, by Cell Signaling Technology (1 mentions) Triptolide, by Cayman Chemical (1 mentions)

1 protocol using pser2 ctd of rpb1

Myc Phosphorylation Profiling by Western Blot

Check if the same lab product or an alternative is used in the 5 most similar protocols

The antibodies used in Western blot were pThr58-Myc (Santa Cruz
Biotechnology, Dallas, Texas, sc-135647), pS62-Myc (Abcam), ERCC3 (A301-337A,
Bethyl Laboratories, Montgomery, TX); antibodies to MYC (#5605),
Rpb1-CTD (#2629), pSer2-CTD of Rpb1 (#8798), pSer2-CTD of Rpb1
(#8807), β-actin (#4967) and α-tubulin
(#2125) were purchased from Cell Signaling Technology, Danvers, MA.
Triptolide was purchased from Cayman Chemical (Ann Arbor, MI) and dissolved in
DMSO as 1 mM stock. Chemotherapy drugs were purchased from the Fox Chase Cancer
Center pharmacy.

Beglyarova N., Banina E., Zhou Y., Mukhamadeeva R., Andrianov G., Bobrov E., Lysenko E., Skobeleva N., Gabitova L., Restifo D., Pressman M., Serebriiskii I.G., Hoffman J.P., Paz K., Behrens D., Khazak V., Jablonski S.A., Golemis E.A., Weiner L.M, & Astsaturov I. (2016). Screening of conditionally reprogrammed patient-derived carcinoma cells identifies ERCC3-MYC interactions as a target in pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 22(24), 6153-6163.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!